This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takimoto, C. H. Search for Related Content PubMed PubMed Citation Articles by Takimoto, C. H.

New Antifolates: Pharmacology and Clinical Applications

NCI-Navy Medical Oncology Branch, National Cancer Institute, Bethesda Naval Hospital, Bethesda, Maryland, USA

Correspondence: Chris H. Takimoto, M.D., Ph.D., NCI-Navy Medical Oncology Branch, National Cancer Institute, Building 8, Room 5101, Bethesda Naval Hospital, Bethesda, MD 20889-5105, USA. Telephone: 301-496-0901; Fax: 301-496-0047; e-mail: ctakim{at}helix.nih.gov

Many new antifolate compounds with unique clinical properties are currently in clinical development. Some of these agents have been rationally designed to circumvent known mechanisms of resistance to methotrexate, the most useful and extensively studied antifolate in clinical practice. Resistance to methotrexate can result from decreased active transport into cells, decreased polyglutamation resulting in enhanced drug efflux from cells, mutations in dihydrofolate reductase which reduce drug binding affinity, and increased expression of dihydrofolate reductase due to gene amplification or increased translational efficiency. As a consequence, the newer antifolates may differ from methotrexate because of increased lipid solubility, improved cellular uptake or increased ability to undergo polyglutamation. Several of these newer agents also uniquely target specific folate-dependent enzymes such as thymidylate synthase or glycinamide ribonucleotide transformylase. Antifolates currently in clinical development include trimetrexate, edatrexate, piritrexim, ZD1694, lometrexol, AG337, LY231514 and 1843U89. This report summarizes the basic pharmacology and potential clinical applications of these promising new agents.

Key Words. Methotrexate • Trimetrexate • Edatrexate • Piritrexim • ZD1694 • Lometrexol • AG337 • LY231514 • 1843U89

This article has been cited by other articles:

				C. L. Sweeney, J. L. Frandsen, C. M. Verfaillie, and R. S. McIvor Trimetrexate Inhibits Progression of the Murine 32Dp210 Model of Chronic Myeloid Leukemia in Animals Expressing Drug-resistant Dihydrofolate Reductase Cancer Res., March 15, 2003; 63(6): 1304 - 1310. [Abstract] [Full Text] [PDF]

				C. L. Sweeney, M. D. Diers, J. L. Frandsen, R. Gunther, C. M. Verfaillie, and R. S. McIvor Methotrexate Exacerbates Tumor Progression in a Murine Model of Chronic Myeloid Leukemia J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1075 - 1084. [Abstract] [Full Text] [PDF]

				Z.-H. Chen, O. I. Olopade, and T. M. Savarese Expression of Methylthioadenosine Phosphorylase cDNA in p16-, MTAP- Malignant Cells: Restoration of Methylthioadenosine Phosphorylase-Dependent Salvage Pathways and Alterations of Sensitivity to Inhibitors of Purine de novo Synthesis Mol. Pharmacol., November 1, 1997; 52(5): 903 - 911. [Abstract] [Full Text]